Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular Comorbidities.

ABSTRACT:

Background

Elderly patients (≥65yr) with advanced prostate cancer and cardiovascular disease (CVD) conditions are often excluded from clinical trials of abiraterone acetate (AA) or enzalutamide (ENZ). Consequently, little is known about the effects of these medications on these vulnerable patients.

Objective

To assess the short-term outcomes of AA and ENZ in patients with pre-existing CVDs.

Design, setting, and participants

A population-based retrospective study. The Surveillance, Epidemiology, and End Results-Medicare-linked database was used to identify prostate cancer patients using AA or ENZ.

Outcome measurements and statistical analysis

The primary endpoint was 6-mo all-cause mortality, analyzed using modified Poisson regression modeling of relative risk (

SUBMITTER: Lu-Yao G 

PROVIDER: S-EPMC6980462 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature